Pooja Prasad, MD
@poojaprasad91
Followers
606
Following
2K
Media
94
Statuses
630
@UCSF AHFTC fellow, a sailor in my dreams @cardionerds #FIT #WIC @wellesleyalums @URochester_SMD @UCD_IM @OHSUCardFellows
Portland, Oregon
Joined December 2011
RT @WomenAs1: 🔬 Mentorship Pairing #2, sponsored by @BridgeBioPharma, winners announced!. Congratulations to @poojaprasad91 & @HannaGaggin….
0
6
0
RT @Dr_DanMD: 🍼 405. @CardioNerds Case Report: Like Mother, Like Son . 💗Explore a case of peripartum cardiomyopathy & infantile HCM unify….
0
9
0
RT @JTDesJardin: @mitralarcade (@UTSWMedCenter) presents on 41W w/ deafness who underwent HM3 w/ use of haptic devices (bed shaker, pager,….
0
3
0
RT @JTDesJardin: Great session on early career and trainee clinical case dilemmas, loved the pairing of trainee clinical case + expert disc….
0
2
0
RT @JTDesJardin: @SebHascoet (@HMLannelongue) PRO for transcutaneous shunts,🎈septostomy outcomes improving, ⬇️RAP, ⬆️CI, helps symptoms, pa….
0
1
0
RT @JTDesJardin: David Morales (@CincyChildrens) CON for transcutaneous shunts. Data for atrial septostomy old and limited in kids. Surgica….
0
1
0
RT @JTDesJardin: @3rdheartsound notes biomarkers in CAV not currently guideline-recommended, but several metabolic (TChol, TGs), inflammato….
0
3
0
RT @JTDesJardin: Lindsey Aurora outlines txt and prevention: aspirin (RCT AERIAL TBD), early PSI/mTOR, LDL control (aim <100 or <50 if CAV….
0
1
0
RT @JTDesJardin: Guillaume Coutance discusses that the natural history of CAV has 4 major trajectories (none, mild/late, severe/late, and s….
0
1
0
RT @JTDesJardin: Tor Clemmensen takes us through CAV pathogenesis: Step 1 endothelial injury and dysfunction (relating to donor, recipient,….
0
1
0
RT @JTDesJardin: Kicking off the PH content @ISHLT with an in depth session on Coming together: improving survival in PAH! #ISHLT2024.
0
2
0
RT @JTDesJardin: @SophiaAirhartMD discusses risk assessment in adults with PAH: achieving low risk status ASAP is key to improved 1 year su….
0
1
0
RT @JTDesJardin: Allen Everett reviews the development and implementation of a risk assessment model in pediatric PAH patients in PPHNet, w….
0
1
0
RT @JTDesJardin: @IsaOpitz on f/u. Persistent PH after PEA common (25%), PVR>5 a/w worse survival. Re-assess at 3-6 mo, RHC needed. Target….
0
2
0
RT @JTDesJardin: Marc de Perrot on interventions. PEA for segmental dz, but BPA+meds beneficial. RACE & MR BPA RCTs (BPA vs rio in non-surg….
0
1
0
RT @JTDesJardin: Rise and shine! ☀️ Early birds at #ISHLT2024 caught the worm with a groundbreaking session on CTEPH. #PVD #CTEPH #SunriseS….
0
1
0
RT @JTDesJardin: In a post-hoc analysis of STELLAR and PULSAR, @mardigomberg stratified pts by cardiac index (cutoff of 2 or 2.5) & sotater….
0
1
0
RT @JTDesJardin: @RaymondBenzaMD's analysis of TORREY compared risk tools (REVEAL 2.0 & Lite 2, COMPERA 2.0, Non-invasive French), showed….
0
1
0
RT @JTDesJardin: 🚀 Dive into the primary data with 'What’s New in Pulmonary Vascular Disease' - the latest updates from registries and cli….
0
1
0